Antiviral agent for use in treatment of cancer

Abstract

The invention relates to an antiviral agent for use in combination with an anticancer agent, for the treatment of cancer. Especially, the invention provides means for the treatment of non-virus-associated cancer.

1 . An antiviral agent for use in combination with an anticancer agent, for the treatment of cancer.  
     
     
         2 . Use of an antiviral agent of the manufacture of a drug for the treatment of cancer, wherein said drug is used in a combined treatment with an anticancer agent.  
     
     
         3 . Use of an antiviral agent for the manufacture of a drug suitable for the treatment of cancer by systemic route.  
     
     
         4 . Antiviral agent or its use according to anyone of claim[[s]]  1  to  3 , wherein the cancer is a virus-associated cancer.  
     
     
         5 . Antiviral agent or its use according to anyone ef claim[[s]]  1  to  3 , wherein the cancer is a non-virus-associated cancer.  
     
     
         6 . Kit of parts comprising an antiviral agent and an anticancer agent, for combined or separate use.  
     
     
         7 . An antiviral agent, its use or a kit comprising an antiviral agent, according to anyone of claims[[s]]  1  to  6 , wherein the antiviral agent is virus non-specific.  
     
     
         8 . An antiviral agent, its use or a kit comprising an antiviral agent, according to anyone of claim[[s]]  1  to  7 , wherein the antiviral agent has a broad-spectrum antiviral activity.  
     
     
         9 . An antiviral agent, its use or a kit comprising an antiviral agent, according to anyone of claim[[s]]  1  to  8 , wherein the antiviral agent has a cytotoxic activity.  
     
     
         10 . An antiviral agent, its use or a kit comprising an antiviral agent, according to anyone of claim[[s]]  1  to  8 , wherein the antiviral agent has an inhibition activity against viral and/or cellular polymerases.  
     
     
         11 . An antiviral agent, its use or a kit comprising an antiviral agent according to anyone of claim[[s]]  1  to  8 , wherein the antiviral agent is a nucleoside phosphonate analogue.  
     
     
         12 . An antiviral agent, its use or a kit comprising an antiviral agent, according to anyone of claim[[s]]  1  to  11 , wherein the antiviral agent is an acyclic nucleoside phosphonate analogue.  
     
     
         13 . An antiviral agent, its use or a kit comprising an antiviral agent, according to  claim 11 , wherein the antiviral agent is HPMPC [(S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine].  
     
     
         14 . An antiviral agent, its use or a kit comprising an antiviral agent, according to anyone of claim[[s]]  1  to  9 , wherein said antiviral agent has an activity against cell cycle regulation, especially through cyclins.  
     
     
         15 . An antiviral agent, its use or a kit comprising an antiviral agent according to anyone of claim[[s]]  1  to  14 , wherein the antiviral agent is active against cyclins.  
     
     
         16 . An antiviral agent, its use or a kit comprising an antiviral agent according to anyone of claim[[s]]  1  to  14 , for use in combination with anticancer radiotherapy.  
     
     
         17 . An antiviral agent, its use or a kit comprising an antiviral agent according to anyone of claim[[s]]  1  to  14 , for use in combination with an anticancer chemotherapeutic agent.  
     
     
         18 . An antiviral agent, its use or a kit comprising an antiviral agent according to anyone of claim[[s]]  1  to  14 , for use in combination with an anticancer immunotherapeutic agent.  
     
     
         19 . An antiviral agent, its use or a kit comprising antiviral agent according to  claim 18 , wherein the immunotherapeutic agent is associated with a cytokin.  
     
     
         20 . An antiviral agent, its use or a kit comprising an antiviral agent according to anyone of claim[[s]]  1  to  14 , for use in combination with at least two anticancer agents chosen among radiation, chemotherapeutic and immunotherapeutic agents.  
     
     
         21 . An antiviral agent, its use or a kit comprising an antiviral agent according to anyone of claim[[s]]  1 - 20  for the manufacture of a drug for systemic treatment of virus-associated cancer in human.  
     
     
         22 . An antiviral agent, it use or a kit comprising an antiviral agent according to anyone of claim[[s ]] 1  to  20 , for the manufacture of a drug for systemic treatment of non-virus-associated cancer in human.  
     
     
         23 . An antiviral agent, its use or a kit comprising an antiviral agent according to anyone of claim[[s]]  1  to  20 , for the manufacture of a drug for intratumoral treatment of cancer in human.  
     
     
         24 . An antiviral agent, its use or a kit comprising an antiviral agent according to  claim 23 , for the systemic treatment of cancer in human.  
     
     
         25 . Use according to anyone of claim[[s]]  1  to  20  or composition according to anyone of  claims 21  to  23 , wherein the antiviral agent is HPMPC and the other anticancer therapeutic agent is radiotherapy.  
     
     
         26 . An antiviral agent, a composition or a use according to anyone of claims  23 - 25 , for the treatment of a virus-associated cancer.  
     
     
         27 . An antiviral agent, a composition or a use according to anyone of  claims 23  to  25 , for the treatment of a non virus-associated cancer.  
     
     
         28 . Antiviral agent or its use according to anye ne of claim[[s]]  4 ,  6  to  20  or composition according to anyone of claims  21 - 24  wherein the viral-associated cancer is associated with an infection by a virus chosen among herpes-, adeno-, polyoma-, papilloma-, Epstein-Barr or Hepatitis DNA viruses.  
     
     
         29 . Antiviral agent or its use according to anyone of claim[[s]]  4 ,  6  to  20 , wherein the cancer is a virus-associated cancer involving infection by EBV or HPV virus.